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1En Route 
Starting a new biotechnology business 
is like performing a high dive: it is 
exciting, frightening, and an ever 
forward and compelling movement 
towards an unknown performance. A 
good, solid business school education 
(which I fortunately have) is like the 
high diving board: it provides a secure 
and resilient jumping off point, but 
in and of itself, it is not enough. One 
must execute the dive. To do that, an 
entrepreneur needs a sense of mission 
and purpose, experience, the ability to 
be flexible and quickly change direction 
if necessary (to rock and roll), and the 
guiding principles of ethics.
Before I became a biotech 
entrepreneur, I spent multiple decades 
in pharmaceutical industry. I first 
started as a copywriter, and, because 
medical advances in the late 20th 
century were novel, I was assigned 
to write about diseases that had been 
previously untreated or ineffectively 
treated. Physicians and patients needed 
to hear about new pharmaceuticals, and 
there were jobs to be had if one could 
communicate well. Pharmaceutical 
copywriting gave therapeutic progress 
a needed voice. 
It had become a fact of life in medicine 
that physicians were becoming just 
too busy to digest or pontificate over 
the Journal of the American Medical 
Association or the New England 
Journal of Medicine every week in 
quest of the newest medicine. So, as 
technology was moving forward at 
an ever-increasing rate and managed 
care was limiting physicians’ time, 
physicians came to rely heavily upon 
commercial communications and 
sales representatives to inform them 
of newly available drugs. Commercial 
communication of information 
replaced the old technique of perusing 
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the literature and having long 
conversations with colleagues. In part, 
the change in post-medical school 
learning techniques did accelerate 
improvements in health as doctors 
learned about and were motivated to 
prescribe the newest drugs. 
This was an efficient process and 
reflected, for the most part, a noble 
goal. As science advanced and 
developed ever better treatments, 
pharmaceutical companies pivoted, 
increasing research spending and 
developing breakthrough drugs. They 
also developed some “me-too” (slightly 
different, but largely duplicative 
therapies); but even these had utility 
for some patients. One size does not 
fit all. There was very good and ethical 
work done by the pharmaceutical 
industry at large and by thousands of 
the industry’s sincere representatives. 
Overall, the system worked: physicians 
learned about and had more effective 
drugs in their armamentarium, the 
pharmaceutical industry thrived, and 
patients benefitted from advancing 
science coupled with the capitalist 
predisposition towards profitability. 
These changes in physician practices 
had measurable impacts on public 
health, too. The large, longitudinal 
Framingham Heart Study started 
in 1948 tracked the cardiovascular 
health of thousands of men, their 
spouses, and their offspring over seven 
decades and counting in Framingham 
Massachusetts.1,2 Longitudinal data 
poured out of the Framingham study 
in the 1960s, 1970s and beyond:3 the 
natural history of congestive heart 
failure,4 epidemiologic features of 
atrial fibrillation,5 the relationship 
of adiposity to the development of 
hypertension,6 along with hundreds 
of other conclusions. As the industry 
raced to develop new cardiovascular 
drugs to respond to these conclusions, 
new anti-hypertensives and other 
varieties of cardiovascular drugs were 
successfully marketed. These drugs 
changed cardiovascular mortality in 
the United States: Deaths from heart 
disease per 100,000 Americans dropped 
from 588 in 1950, to 492 in 1970, to 321 
in 1990, to 187 in 2014 – a dramatic 
tumble.7 This was largely due to the 
results of studies like Framingham, the 
industry’s responsiveness in developing 
drugs to treat the causes and effects 
of cardiovascular pathology, and the 
massive efforts of the pharmaceutical 
industry to communicate and sell 
their wares. Everyone won: patients 
lived longer, doctors had a bigger and 
better range of therapies to use, drug 
companies made money along with 
their advances.
But then came the lawsuits: sales 
representatives went “off script,” 
companies pushed drugs “off label” 
(that is, for medical indications for 
which the FDA had not approved) 
and a thousand other things that 
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made consumers angry and lawyers’ 
practices boom. The rock and roll days 
of the industry from the 1970s to 1990s, 
slowed, and companies had to face the 
legal music.
By 2009, the pharmaceutical industry 
had largely reinvented itself. By late 
2008, it published a new code of ethics 
that described ethical interactions 
with healthcare professionals.8 More 
and more companies offered payment 
assistance for expensive drugs;9 
companies were willing (or forced by 
insurers) to accept payment based 
on product efficacy;10 and in general, 
by 2016 the pharmaceutical industry 
and its ethics were constantly in the 
news, serving as the base for political 
rhetoric, and constantly on the minds 
of increasingly aging American 
consumers.
So what is a pharmaceutical or biotech 
entrepreneur to ethically do in the 21st 
century? Obviously provide a market 
disruptive, health outcome-improving 
drug—and do so quickly, affordably, 
accessibly and ethically. But none of 
those things are easy.
Jumping off the diving board into the 
market first requires discovery and 
development of a superior product. 
Then, it demands an unfailing ability 
to conceptualize the product’s position 
in the pharmaceutical armamentarium, 
the ability to execute access to patients 
and payers, to obtain physician 
approval and prescribing. And, not 
unlike the athletes whose sport is the 
high dive, launching a new biotech 
drug demands excellent training and 
continuous preparation for its market 
entry and subsequent trajectory. The 
lessons of the 20th century and the 
industry sideshow of unscrupulous 21st 
century entrepreneurs have also placed 
additional demands on today’s newly 
formed biotech or pharmaceutical 
company: it must be built with a strong 
underpinning of ethics. If not, the 
company will crash, money will be 
wasted, and the public good will suffer.
Alexei Marcoux of Creighton 
University has studied entrepreneurship 
and provides some insight into the 
process. In his view, entrepreneurs 
undo the existing order in order to 
achieve a better result. Dr. Marcoux 
reviews several theories of how this 
is done:11 Knight who theorizes that 
entrepreneurs are those who are willing 
to bear uncertainty; Kirzner who 
believes that entrepreneurs are those 
who perceive opportunity; Schumpeter 
who believes that entrepreneurship 
is an act of creation. Or, to be more 
precise, entrepreneurship is an act of 
creative destruction of the status quo.
None of this is for the faint hearted. 
Think about the parallels in music: 
Elvis Presley creatively destroyed 1950s 
pop and the charming “doggies in the 
window,” but even Elvis needed drugs 
and carbohydrates to get through it 
all. The Rolling Stones had their own 
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acts of creative destruction—famously 
witnessed in hotel rooms and on 
island vacations. Synthesizers did in 
some instruments, and tapes, CDs 
and streaming relegated the once-
ubiquitous vinyl to vague industrial 
uses. Creative destruction is first 
destructive, but it is so in the hopes 
that in the end, creativity triumphs 
and products and markets get better. 
For biotech entrepreneurs, the bar is 
even higher. Products, markets, and 
longevity or quality of life must get 
better in order for the entrepreneur to 
succeed. 
But, alas, the dis-equilibrating force 
of biotech entrepreneurship can be 
distorted in many unethical ways. 
Martin Shkreli of Turing certainly 
attempted disequilibrium for markets, 
but did not offer up a superior, creative 
product or bear much personal 
uncertainty. And though he “perceived 
opportunity” as Kirzner suggests, 
it appeared to be only for personal 
financial gain. Arguably Shkreli has not 
provided any benefit to society (except 
to become a case study of what NOT 
to do as a pharmaceutical company 
CEO) and has not displayed what 
most individuals would consider to be 
ethics.12
So what about business ethics in the 
realm of biotech entrepreneurship? 
Exactly who or what comprises the new 
corporation and who must be ethical? 
Who is that entrepreneur standing at 
the edge of the diving platform? The 
CEO? Chief scientist? Commercial 
officers? Legal counsel? All of them…
and then some. 
Alexei Marcoux also has some thoughts 
on the “who” of entrepreneurship. 
In a seminal paper entitled Business 
Ethics,13 Marcoux argues that the ethics 
of a corporation affect all who work 
there and all who attempt to move the 
business forward. Marcoux expands 
on Solomon’s work that defined the 
existence of multiple levels of ethics 
in the corporation (even if it is a small 
biotech!): micro, macro, and molar. 
Micro-ethics are the ethics that I, 
as an individual, bring to my work. 
This occurs on a daily basis, affects 
everything I do, and ideally drives me 
towards ethically mediated success. 
Macro ethics concerns the institutional 
or cultural rules of commerce for the 
entire society. What does society expect 
of a new company trying to innovate in 
an old industry….and an industry that 
is committed to human well being at 
that? Lastly, molar ethics concern the 
basic unit of commerce globally: the 
corporation. 
For aspiring biotechnology 
entrepreneurs who have a potent mix 
of drive, fear of failure, willingness to 
do good, and a mission to stay within 
ethical guidelines to develop their 
product and move the industry and the 
public’s health towards a better future, 
Marcoux’ analysis presents a tall, multi-
Ethics, Drugs, and Rock and Roll: On the Integration of 
Bioethics into the Entrepreneurial Life
5En Route 
faceted order. In short, ethics on every 
level of the corporation is essential. 
This would be difficult enough if 
science were not moving inexorably 
forward. Today’s great scientific thesis 
is eclipsed by tomorrow’s discovery. 
A biotech entrepreneur, like every 
entrepreneur, needs focus, but also 
needs the flexibility to shift gears as the 
science advances and to perceive new 
opportunity. Entering a market with 
yesterday’s technology will not achieve 
market acceptance or access. In short, 
being late means you have wasted your 
time, your money and perhaps years of 
effort. This pressure cooker might drive 
many to unethical behavior, if it were 
not for the lessons and lawsuits of the 
recent past and the ethical commitment 
of the entrepreneur.
The progress of the pharmaceutical 
industry in the 1950s and beyond was 
a combination of discovery, commerce, 
and some would argue, a fluorescent 
mix of ethical and unethical behavior. 
In the upcoming 2020s, the progress 
of the biotech industry will have the 
same mixture, but will also have to take 
off from a higher ethical platform as a 
consequence of the errors and ethical 
failings of the past. This is all possible, 
but to do so requires consistent ethical 
attention to intent, purpose, and 
execution. And as every Olympian 
diver in training knows, that effort and 
drive towards excellence is personally 
rewarding and very meaningful. I am 
sure many a biotech entrepreneur, and 
rock musician would agree.
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